The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management

Article Endocrinology & Metabolism

Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Stephanie Kullmann et al.

Summary: SGLT2 inhibitors could be a pharmacological approach to reverse brain insulin resistance and improve overall metabolism in prediabetic individuals.

DIABETES CARE (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts

Raffaele Marfella et al.

Summary: The early pathogenesis of human diabetic cardiomyopathy is associated with overexpression of JunD/PPAR-gamma and lipid accumulation, which can be attenuated by treatment with SGLT2 inhibitors in diabetic patients.

METABOLISM-CLINICAL AND EXPERIMENTAL (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Effects of Sodium-Glucose Cotransporter 2 on Amputation Events: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials

Ray Meng See et al.

Summary: The systematic review and meta-analysis showed that SGLT2 inhibitors do not increase the risk of amputation events, and there were no significant differences across different types, baseline populations, and duration of use.

PHARMACOLOGY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Sodium-glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice

Miho Murashima et al.

Summary: This study revealed that the use of SGLT2i was associated with higher hemoglobin levels and lower prevalence of anemia in real clinical practice.

JOURNAL OF DIABETES INVESTIGATION (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs

Dario Giugliano et al.

Summary: According to the results of network meta-analysis, GLP-1RA and SGLT-2 inhibitors are superior to DPP-4 inhibitors in reducing the risk of cardiorenal outcomes. Compared with DPP-4 inhibitors, SGLT-2 inhibitors have a more significant effect in reducing cardiovascular and overall mortality, while GLP-1RA only reduces overall mortality. There is no significant difference between GLP-1RA and SGLT-2 inhibitors in the risks of MACE, nonfatal MI, nonfatal stroke, cardiovascular, and overall mortality. SGLT-2 inhibitors are superior to GLP-1RA in reducing the risk of hospitalization for heart failure and renal outcomes. Only GLP-1RA can reduce the risk of nonfatal stroke.

CARDIOVASCULAR DIABETOLOGY (2022)

添加到收藏夹

Review Urology & Nephrology

Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis

Mehmet Kanbay et al.

Summary: This study included 17 randomized, double-blind, placebo-controlled studies with a total of 14,748 evaluated patients, showing that SGLT2i therapy significantly increased hemoglobin and hematocrit levels compared to placebo.

INTERNATIONAL UROLOGY AND NEPHROLOGY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Acute kidney injury in Japanese type 2 diabetes patients receiving sodium-glucose cotransporter 2 inhibitors: A nationwide cohort study

Takeshi Horii et al.

Summary: This retrospective study in Japanese patients with type 2 diabetes found that factors associated with an increased risk of acute kidney injury after treatment with sodium-glucose cotransporter 2 inhibitors included being male, older age, lower body mass index, history of heart failure, and more frequent use of diuretics. These findings highlight the importance of evaluating clinical risk factors before prescribing sodium-glucose cotransporter 2 inhibitors to prevent acute kidney injury.

JOURNAL OF DIABETES INVESTIGATION (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Stephanie Kullmann et al.

Summary: Insulin action in the human brain plays an important role in regulating food intake and whole-body insulin sensitivity. This study found that treatment with empagliflozin for 8 weeks can restore hypothalamic insulin sensitivity in individuals with prediabetes, suggesting that SGLT2 inhibition may be a potential pharmacological approach to reverse brain insulin resistance and improve overall metabolism.

DIABETES CARE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation

Detmar Kolijn et al.

Summary: This study demonstrated that empagliflozin reduces inflammation and oxidative stress in patients with HFpEF, thereby improving the NO-sGC-cGMP cascade and PKGI alpha activity. This leads to a decrease in pathological cardiomyocyte stiffness in HFpEF.

CARDIOVASCULAR RESEARCH (2021)

添加到收藏夹

Review Peripheral Vascular Disease

SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives

Alexia Piperidou et al.

Summary: Chronic kidney disease is a major public health issue and strict blood pressure control and renin-angiotensin system (RAS) blocker use are essential in its treatment. SGLT-2 inhibitors have shown promising nephroprotective properties in patients with type 2 diabetes mellitus, reducing albuminuria and the risk of hard renal outcomes.

JOURNAL OF HUMAN HYPERTENSION (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials

Victor Okunrintemi et al.

Summary: SGLT2 inhibitors significantly lower the risk of incident atrial fibrillation in high-risk individuals, regardless of diabetes status. However, further research is needed to evaluate its clinical significance.

DIABETES OBESITY & METABOLISM (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials

Xu-Bin Wei et al.

Summary: Different drug treatments have varying efficacy in reducing cardiorenal events in type 2 diabetic adults, with some drugs being more effective at preventing specific cardiorenal endpoints.

PRIMARY CARE DIABETES (2021)

添加到收藏夹

Article Urology & Nephrology

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Katherine R. Tuttle et al.

Summary: Research shows that the use of SGLT2 inhibitors can reduce the risks of kidney disease and cardiovascular events in patients with type 2 diabetes.

AMERICAN JOURNAL OF KIDNEY DISEASES (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis

Yi-Wen Yu et al.

Summary: The study found that SGLT2 inhibitors had no significant impact on cardiac structural parameters in type 2 diabetes patients, but improved left ventricular ejection fraction in heart failure patients. It also had a positive effect on cardiac diastolic function, plasma NT-proBNP level, and KCCQ score.

CARDIOVASCULAR DIABETOLOGY (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes

Dario Giugliano et al.

Summary: The review summarizes the progress in the treatment and prevention of cardiorenal complications in patients with T2D using SGLT-2 inhibitors, with a particular focus on age, the role of prevention, and the potential extension of their benefits.

CARDIOVASCULAR DIABETOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis

Takayuki Yamada et al.

Summary: In patients with type 2 diabetes mellitus and chronic kidney disease, SGLT-2 inhibitors were found to decrease the risk of cardiovascular and renal events, while GLP-1 RAs did not. SGLT-2 inhibitors were associated with a lower risk of renal events compared to GLP-1 RAs.

CARDIOVASCULAR DIABETOLOGY (2021)

添加到收藏夹

Article Urology & Nephrology

Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury

Min Zhao et al.

Summary: The study compared the effects of DPP-4 inhibitors, GLP-1RAs, and SGLT2 inhibitors on AKI risk using network meta-analysis. Results showed that SGLT2 inhibitors had a lower risk of AKI compared to DPP-4 inhibitors and GLP-1RAs, with SGLT2 inhibitors having the highest probability of being the safest intervention. This suggests that SGLT2 inhibitors may be a preferred treatment option for reducing AKI risk.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure

Julius L. Katzmann et al.

Summary: This study revealed an association between genetic variations in the SGLT2 gene and the risk of heart failure, which was mediated by several mechanisms and independent of the presence of type 2 diabetes or previous CAD events. The genetic score was found to be associated with lower heart failure risk and various metabolic factors, providing insights into the potential mechanisms underlying the cardioprotective effects of SGLT2 inhibitors.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations

Chin Meng Khoo et al.

Summary: SGLT-2 inhibitors have been shown to significantly reduce albuminuria and the risk of hard renal outcomes in Asian patients with DKD, as well as positively impact cardiovascular outcomes. Despite a decline in glucose-lowering efficacy in patients with low eGFR, reductions in body weight, blood pressure, and an increase in haematocrit were sustained.

DIABETES OBESITY & METABOLISM (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study

Seung Jin Han et al.

Summary: New users of SGLT2 inhibitors, compared with DPP-4 inhibitors, had a lower risk of hospitalization for heart failure, all-cause death, and stroke, but a similar risk of myocardial infarction. The risks of diabetic ketoacidosis, bone fracture, and severe hypoglycemia were similar between both groups, although genital infection and UTI were more frequent among new users of SGLT2 inhibitors.

DIABETES OBESITY & METABOLISM (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials

Giovanni Antonio Silverii et al.

Summary: The meta-analysis of 21 randomized clinical trials on SGLT2 inhibitors showed a significant reduction in all-cause mortality, with factors such as the proportion of Asian subjects recruited and the proportion of Caucasian patients influencing the treatment effect.

DIABETES OBESITY & METABOLISM (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF

Pooja Dewan et al.

Summary: In patients with heart failure with reduced ejection fraction, approximately one in eight individuals also had chronic obstructive pulmonary disease. Patients with COPD had a higher risk of adverse outcomes, but the efficacy of dapagliflozin was consistent in patients with and without COPD.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Review Medicine, Research & Experimental

Pharmacological treatment of hyperglycemia in type 2 diabetes

Simeon I. Taylor et al.

Summary: Diabetes mellitus is a significant public health issue, with pharmacotherapy aiming to prevent complications. Clinical trials have shown that intensive glycemic control can slow the progression of complications, with some drugs also demonstrating cardiovascular benefits and slowed progression of diabetic kidney disease.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Urology & Nephrology

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Megumi Oshima et al.

Summary: The study found that in patients with type 2 diabetes and chronic kidney disease, the use of canagliflozin may lead to an acute drop in eGFR, but this did not affect long-term eGFR trajectories and safety outcomes.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease

Tamique Mason et al.

Summary: The study shows that empagliflozin treatment for 6 months can reduce ECV, iECV, and LVMi in individuals with T2DM and CAD, with no impact on MMP-2 and sST2. Further research on the mechanisms of empagliflozin-induced reverse remodeling is needed.

JACC-CARDIOVASCULAR IMAGING (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone

Kyu Yong Cho et al.

Summary: Dapagliflozin may be more beneficial than pioglitazone for patients with NAFLD, and improvements in FLI are closely related to glycemic control.

JOURNAL OF DIABETES INVESTIGATION (2021)

添加到收藏夹

Review Medicine, General & Internal

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Suetonia C. Palmer et al.

Summary: This network meta-analysis evaluated the effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk levels. The study found that both classes of drugs lowered mortality and improved cardiovascular outcomes, with notable differences in effects between the two agents. Additional benefits and adverse effects varied across different risk groups.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Guideline recommendations and the positioning of newer drugs in type 2 diabetes care

Nikolaus Marx et al.

Summary: Recent cardiovascular outcome trials in high-risk type 2 diabetes patients have improved our understanding of GLP-1 receptor agonists and SGLT2 inhibitors. However, differences in recommendations between endocrinologists and cardiologists may hinder evidence-based treatment for patients. Coordinated action is needed to integrate management approaches and ensure appropriate treatment for diabetes and cardiorenal disease patients.

LANCET DIABETES & ENDOCRINOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials

Alessandro Mantovani et al.

Summary: The study showed that SGLT-2 inhibitors are promising treatment options for NAFLD, significantly decreasing liver enzyme levels and liver fat content.

METABOLITES (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial

Michael E. Nassif et al.

Summary: This study found that using dapagliflozin can lead to improvement in lung fluid volume in patients with HF, as measured by remote dielectric sensing. This discovery provides a clue to unraveling the mechanisms of benefit of SGLT2 inhibitors in heart failure.

DIABETES OBESITY & METABOLISM (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Pharmacogenetics of novel glucose-lowering drugs

Wolfgang Rathmann et al.

Summary: Current studies have identified genetic variants associated with response to DPP-4i, GLP-1 RA, and SGLT2i, but replication studies are lacking. Most studies have been candidate gene-based, indicating that genome-wide association studies may offer more promising insights in the future.

DIABETOLOGIA (2021)

添加到收藏夹

Review Medicine, General & Internal

Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease A protocol for systematic review and meta-analysis

Baisong Yu et al.

Summary: The study evaluated the effects of SGLT2 inhibitors on renal outcomes in type 2 diabetes mellitus patients with chronic kidney disease. It found that SGLT2 inhibitors did not significantly affect kidney function, reduced urine albumin/creatinine ratio, and decreased the incidence of acute kidney injury in this population.

MEDICINE (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis

Yaling Bai et al.

Summary: SGLT2 inhibitors show significant reduction in risk of adverse events across different renal function at baseline, with no significant differences observed in safety outcomes, indicating the potential for broader use of these inhibitors in clinical practice.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial

Jesper Jensen et al.

Summary: SGLT2 inhibitors show promise as a treatment option for heart failure patients with reduced ejection fraction. This study aimed to investigate the effects of empagliflozin on various renal parameters in these patients. The results demonstrated that empagliflozin treatment led to reductions in estimated extracellular volume, estimated plasma volume, and measured GFR, suggesting that fluid volume changes may play a role in the beneficial effects of SGLT2 inhibitors.

LANCET DIABETES & ENDOCRINOLOGY (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis

Chloe Wong et al.

Summary: SGLT2i is an effective treatment for improving NAFLD among patients with type 2 diabetes, showing significant improvements in liver fat content, biochemical markers, inflammatory markers, etc. Further studies are needed to confirm its effects on NAFLD.

FRONTIERS IN ENDOCRINOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis

Hang-Long Li et al.

Summary: This study found that SGLT2 inhibitors can reduce the risk of patients developing atrial fibrillation, embolic stroke, atrial fibrillation/flutter, and ventricular tachycardia. The associations were consistent across different baseline conditions and types of SGLT2 inhibitors used.

CARDIOVASCULAR DIABETOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors

Husam Ghanim et al.

Summary: This study demonstrates that treatment with dapagliflozin can significantly reduce systolic blood pressure in patients with type 2 diabetes, suppress the expression of angiotensin II and angiotensinogen, and increase levels of vasodilators.

DIABETES OBESITY & METABOLISM (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals

Donna Shu-Han Lin et al.

Summary: This study found that SGLT2is demonstrate overall good safety profile, but may increase the risk of genital infections while providing protection against AKI. The risk of amputation is higher in ASCVD patients, and close monitoring of patients is essential after the use of SGLT2is.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure

Jean-Claude Marshall et al.

Summary: Ertugliflozin is primarily metabolized by UGT1A9, with its exposure increasing in a dose-proportional manner. UGT1A9 genotype has minimal impact on Ertugliflozin exposure, and no dose adjustment is needed for healthy subjects with specific UGT1A9 variants assessed in the study.

JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial

Samuel Dagogo-Jack et al.

Summary: In VERTIS CV, ertugliflozin demonstrated significant reductions in HbA1c levels, body weight, and SBP, as well as maintenance of eGFR in patients with CKD stage 3, with generally good tolerability.

BMJ OPEN DIABETES RESEARCH & CARE (2021)

添加到收藏夹

Review Medicine, General & Internal

Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review

Jorge I. Fonseca-Correa et al.

Summary: SGLT2 inhibitors have shown significant benefits in renal and cardiovascular protection through various mechanisms, including reducing blood glucose, weight loss, improving insulin sensitivity, lipid metabolism, and lowering blood pressure. These changes contribute to improved cardiovascular function and are central to the cardiovascular benefits of SGLT2 inhibitors.

FRONTIERS IN MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort

Fateen Ata et al.

Summary: This retrospective cohort study found that the prevalence of euglycemic diabetic ketoacidosis (EuDKA) in type 2 diabetes patients taking SGLT2 inhibitors was 0.43%, with infection being the most common trigger. Among EuDKA patients, the highest prevalence was associated with the use of canagliflozin.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Endocrinology & Metabolism

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population

Lianglan Shen et al.

Summary: The study found that SGLT2 inhibitors have a lower risk of causing AKI compared to other classes of drugs, with various medications such as ibuprofen, celecoxib associated with increased rates of AKI.

DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2021)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus

Kosuke Mozawa et al.

Summary: Empagliflozin prevented kidney functional decline in patients with AMI and T2DM, especially in those with baseline eGFR >= 60 mL/min/1.73 m(2). Early administration of sodium-glucose cotransporter 2 inhibitors in these patients is considered desirable for renal protection.

ESC HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

Matthew M. Y. Lee et al.

Summary: The study confirmed the effectiveness of sodium-glucose cotransporter 2 inhibitor empagliflozin in reducing left ventricular volumes in patients with HFrEF, favoring reverse left ventricular remodeling. This may be one of the mechanisms by which sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization and mortality in HFrEF.

CIRCULATION (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study)

Kyu Yong Cho et al.

DIABETES OBESITY & METABOLISM (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report

Megumi Yasuda et al.

JOURNAL OF DIABETES INVESTIGATION (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

Ayako Fuchigami et al.

CARDIOVASCULAR DIABETOLOGY (2020)

添加到收藏夹

Review Public, Environmental & Occupational Health

Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis

Huilin Tang et al.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)

添加到收藏夹

Review Public, Environmental & Occupational Health

Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials

Dandan Li et al.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials

Jiali Liu et al.

DIABETES OBESITY & METABOLISM (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis

Yoshio Sumida et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Mark C. Petrie et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Review Medicine, General & Internal

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes A Systematic Review and Network Meta-analysis

Apostolos Tsapas et al.

ANNALS OF INTERNAL MEDICINE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial

Francesco Cosentino et al.

CIRCULATION (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial

Atsushi Tanaka et al.

JOURNAL OF DIABETES INVESTIGATION (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes:A Meta-Analysis of 51 Randomized Clinical Trials

Fang-Hong Shi et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J. L. Heerspink et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study

Kristian B. Filion et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

David C Wheeler et al.

Lancet Diabetes & Endocrinology (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Amino-Terminal Pro-B-Type Natriuretic Peptide Implications for Cardiovascular Risk Reduction

James L. Januzzi et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

添加到收藏夹

Review Endocrinology & Metabolism

The association of sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews

Ryan Pelletier et al.

ENDOCRINOLOGY DIABETES & METABOLISM (2020)

添加到收藏夹

Review Medicine, Research & Experimental

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?

Yoshifumi Saisho

DISEASES (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors A State-of-the-Art Review

Gary D. Lopaschuk et al.

JACC-BASIC TO TRANSLATIONAL SCIENCE (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials

L. Cheng et al.

DIABETES & METABOLISM (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia

Linong Ji et al.

DIABETES OBESITY & METABOLISM (2019)

添加到收藏夹

Review Medicine, General & Internal

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis

Jennifer R. Donnan et al.

BMJ OPEN (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis

Heinz Drexel et al.

BIOSCIENCE REPORTS (2019)

添加到收藏夹

Article Medicine, General & Internal

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

V. Perkovic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Dapagliflozin: A Review in Type 2 Diabetes

Sohita Dhillon

DRUGS (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial

Subodh Verma et al.

CIRCULATION (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

Zien Zhou et al.

DIABETOLOGIA (2019)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial

Ofri Mosenzon et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

添加到收藏夹

Article Geriatrics & Gerontology

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial

Pedro Monteiro et al.

AGE AND AGEING (2019)

添加到收藏夹

Article Medicine, General & Internal

Fracture Risk After Initiation of Use of Canagliflozin A Cohort Study

Michael Fralick et al.

ANNALS OF INTERNAL MEDICINE (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial

Silvina Gallo et al.

DIABETES OBESITY & METABOLISM (2019)

添加到收藏夹

Review Medicine, General & Internal

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Thomas A. Zelniker et al.

LANCET (2019)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

S. D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Editorial Material Endocrinology & Metabolism

Sarcopenia, frailty circle and treatment with sodium-glucose cotransporter 2 inhibitors

Takashi Sasaki

JOURNAL OF DIABETES INVESTIGATION (2019)

添加到收藏夹

Article Endocrinology & Metabolism

SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels

Takayoshi Suga et al.

MOLECULAR METABOLISM (2019)

添加到收藏夹

Review Endocrinology & Metabolism

The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon Like Peptide -1 Receptor Agonists

Chan-Hee Jung et al.

JOURNAL OF OBESITY & METABOLIC SYNDROME (2019)

添加到收藏夹

Review Endocrinology & Metabolism

A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus

Gita Chawla et al.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program

Karin Radholm et al.

CIRCULATION (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials

D. Li et al.

DIABETES & METABOLISM (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

Mohammad Shafi Kuchay et al.

DIABETES CARE (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

Richard E. Pratley et al.

DIABETES OBESITY & METABOLISM (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)

Patrick B. Ryan et al.

DIABETES OBESITY & METABOLISM (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study

Ronnie Aronson et al.

DIABETES OBESITY & METABOLISM (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Jan W. Eriksson et al.

DIABETOLOGIA (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Ertugliflozin: First Global Approval

Anthony Markham

DRUGS (2018)

添加到收藏夹

Review Endocrinology & Metabolism

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2018 EXECUTIVE SUMMARY

Alan J. Garber et al.

ENDOCRINE PRACTICE (2018)

添加到收藏夹

Review Medicine, General & Internal

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis

Sean L. Zheng et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Patatin-like phospholipase domain-containing protein 3 promotes transfers of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets

Matthew A. Mitsche et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

W. Timothy Garvey et al.

METABOLISM-CLINICAL AND EXPERIMENTAL (2018)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis

Muhammad Shariq Usman et al.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

Vlado Perkovic et al.

LANCET DIABETES & ENDOCRINOLOGY (2018)

添加到收藏夹

Article Endocrinology & Metabolism

A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss

Maria J. Pereira et al.

DIABETES THERAPY (2018)

添加到收藏夹

Article Endocrinology & Metabolism

A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss

Maria J. Pereira et al.

DIABETES THERAPY (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

Kenneth W. Mahaffey et al.

CIRCULATION (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies et al.

DIABETES CARE (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study

Samuel Dagogo-Jack et al.

DIABETES OBESITY & METABOLISM (2018)

添加到收藏夹

Article Endocrinology & Metabolism

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi et al.

DIABETES CARE (2018)

添加到收藏夹

Review Public, Environmental & Occupational Health

Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia

Auryan Szalat et al.

DRUG SAFETY (2018)

添加到收藏夹

Article Urology & Nephrology

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

Hiddo J. L. Heerspink et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes

Heike Zimdahl et al.

PHARMACOGENETICS AND GENOMICS (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies

James Thrasher

AMERICAN JOURNAL OF CARDIOLOGY (2017)

添加到收藏夹

Letter Endocrinology & Metabolism

Bladder cancer in the EMPA-REG OUTCOME trial

Sven Kohler et al.

DIABETOLOGIA (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis

Darin Ruanpeng et al.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)

添加到收藏夹

Article Endocrinology & Metabolism

SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials

Huilin Tang et al.

DIABETOLOGIA (2017)

添加到收藏夹

Review Endocrinology & Metabolism

Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials

Matthew J. Levine

CURRENT DIABETES REVIEWS (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

Mikhail Kosiborod et al.

CIRCULATION (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

Toshiyuki Hayashi et al.

CARDIOVASCULAR DIABETOLOGY (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus

Eef Hoeben et al.

CLINICAL PHARMACOKINETICS (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications

Hiddo J. L. Heerspink et al.

CIRCULATION (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials

H. L. Tang et al.

DIABETES OBESITY & METABOLISM (2016)

添加到收藏夹

Letter Endocrinology & Metabolism

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

Paola Fioretto et al.

DIABETOLOGIA (2016)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study

Michael A. Weber et al.

LANCET DIABETES & ENDOCRINOLOGY (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

Juan P. Frias et al.

LANCET DIABETES & ENDOCRINOLOGY (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

Jason H. Y. Wu et al.

LANCET DIABETES & ENDOCRINOLOGY (2016)

添加到收藏夹

Article Medicine, Research & Experimental

Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study

Takashi Kadowaki et al.

ADVANCES IN THERAPY (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

Michael Roden et al.

CARDIOVASCULAR DIABETOLOGY (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

Rimei Nishimura et al.

CARDIOVASCULAR DIABETOLOGY (2015)

添加到收藏夹

Article Pharmacology & Pharmacy

In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans

Stephan Francke et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

Caroline Bonner et al.

NATURE MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Endocrinology & Metabolism

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

Ilkka Tikkanen et al.

DIABETES CARE (2015)

添加到收藏夹

Article Endocrinology & Metabolism

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Serge A. Jabbour et al.

DIABETES CARE (2014)

添加到收藏夹

Article Endocrinology & Metabolism

Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin

Sunder Mudaliar et al.

DIABETES TECHNOLOGY & THERAPEUTICS (2014)

添加到收藏夹

Review Pharmacology & Pharmacy

Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes

Greg L. Plosker

DRUGS (2014)

添加到收藏夹

Review Pharmacology & Pharmacy

Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Lesley J. Scott

DRUGS (2014)

添加到收藏夹

Article Medicine, Research & Experimental

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Ele Ferrannini et al.

JOURNAL OF CLINICAL INVESTIGATION (2014)

添加到收藏夹

Article Endocrinology & Metabolism

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

Martin Ridderstrale et al.

LANCET DIABETES & ENDOCRINOLOGY (2014)

添加到收藏夹

Article Endocrinology & Metabolism

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

Anthony H. Barnett et al.

LANCET DIABETES & ENDOCRINOLOGY (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial

Bruce Neal et al.

AMERICAN HEART JOURNAL (2013)

添加到收藏夹

Review Medicine, General & Internal

Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis

Despoina Vasilakou et al.

ANNALS OF INTERNAL MEDICINE (2013)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Clifford J. Bailey et al.

BMC MEDICINE (2013)

添加到收藏夹

Article Endocrinology & Metabolism

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

Ele Ferrannini et al.

DIABETES CARE (2013)

添加到收藏夹

Review Endocrinology & Metabolism

Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus

L. H. Chen et al.

DIABETES OBESITY & METABOLISM (2013)

添加到收藏夹

Article Endocrinology & Metabolism

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

F. J. Lavalle-Gonzalez et al.

DIABETOLOGIA (2013)

添加到收藏夹

Article Pharmacology & Pharmacy

Canagliflozin: First Global Approval

Shelley Elkinson et al.

DRUGS (2013)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

William T. Cefalu et al.

LANCET (2013)

添加到收藏夹

Review Pharmacology & Pharmacy

SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?

Anke Toenjes et al.

PHARMACOGENOMICS (2013)

添加到收藏夹

Article Endocrinology & Metabolism

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

Michael Roden et al.

LANCET DIABETES & ENDOCRINOLOGY (2013)

添加到收藏夹

Article Pharmacology & Pharmacy

Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis

Uta Enigk et al.

PHARMACOGENOMICS (2011)

添加到收藏夹

Review Medicine, General & Internal

Epidemic obesity and type 2 diabetes in Asia

Kun-Ho Yoon et al.

LANCET (2006)

添加到收藏夹

The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management

相关参考文献